Cargando…
Alchemical analysis of FDA approved drugs
Chemical space maps help visualize similarities within molecular sets. However, there are many different molecular similarity measures resulting in a confusing number of possible comparisons. To overcome this limitation, we exploit the fact that tools designed for reaction informatics also work for...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561545/ https://www.ncbi.nlm.nih.gov/pubmed/38013905 http://dx.doi.org/10.1039/d3dd00039g |
_version_ | 1785117947470020608 |
---|---|
author | Orsi, Markus Probst, Daniel Schwaller, Philippe Reymond, Jean-Louis |
author_facet | Orsi, Markus Probst, Daniel Schwaller, Philippe Reymond, Jean-Louis |
author_sort | Orsi, Markus |
collection | PubMed |
description | Chemical space maps help visualize similarities within molecular sets. However, there are many different molecular similarity measures resulting in a confusing number of possible comparisons. To overcome this limitation, we exploit the fact that tools designed for reaction informatics also work for alchemical processes that do not obey Lavoisier's principle, such as the transmutation of lead into gold. We start by using the differential reaction fingerprint (DRFP) to create tree-maps (TMAPs) representing the chemical space of pairs of drugs selected as being similar according to various molecular fingerprints. We then use the Transformer-based RXNMapper model to understand structural relationships between drugs, and its confidence score to distinguish between pairs related by chemically feasible transformations and pairs related by alchemical transmutations. This analysis reveals a diversity of structural similarity relationships that are otherwise difficult to analyze simultaneously. We exemplify this approach by visualizing FDA-approved drugs, EGFR inhibitors, and polymyxin B analogs. |
format | Online Article Text |
id | pubmed-10561545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | RSC |
record_format | MEDLINE/PubMed |
spelling | pubmed-105615452023-10-10 Alchemical analysis of FDA approved drugs Orsi, Markus Probst, Daniel Schwaller, Philippe Reymond, Jean-Louis Digit Discov Chemistry Chemical space maps help visualize similarities within molecular sets. However, there are many different molecular similarity measures resulting in a confusing number of possible comparisons. To overcome this limitation, we exploit the fact that tools designed for reaction informatics also work for alchemical processes that do not obey Lavoisier's principle, such as the transmutation of lead into gold. We start by using the differential reaction fingerprint (DRFP) to create tree-maps (TMAPs) representing the chemical space of pairs of drugs selected as being similar according to various molecular fingerprints. We then use the Transformer-based RXNMapper model to understand structural relationships between drugs, and its confidence score to distinguish between pairs related by chemically feasible transformations and pairs related by alchemical transmutations. This analysis reveals a diversity of structural similarity relationships that are otherwise difficult to analyze simultaneously. We exemplify this approach by visualizing FDA-approved drugs, EGFR inhibitors, and polymyxin B analogs. RSC 2023-08-30 /pmc/articles/PMC10561545/ /pubmed/38013905 http://dx.doi.org/10.1039/d3dd00039g Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Chemistry Orsi, Markus Probst, Daniel Schwaller, Philippe Reymond, Jean-Louis Alchemical analysis of FDA approved drugs |
title | Alchemical analysis of FDA approved drugs |
title_full | Alchemical analysis of FDA approved drugs |
title_fullStr | Alchemical analysis of FDA approved drugs |
title_full_unstemmed | Alchemical analysis of FDA approved drugs |
title_short | Alchemical analysis of FDA approved drugs |
title_sort | alchemical analysis of fda approved drugs |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561545/ https://www.ncbi.nlm.nih.gov/pubmed/38013905 http://dx.doi.org/10.1039/d3dd00039g |
work_keys_str_mv | AT orsimarkus alchemicalanalysisoffdaapproveddrugs AT probstdaniel alchemicalanalysisoffdaapproveddrugs AT schwallerphilippe alchemicalanalysisoffdaapproveddrugs AT reymondjeanlouis alchemicalanalysisoffdaapproveddrugs |